

**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (Currently amended). An injectable chemotherapeutic pharmaceutical composition consisting of a halogenated xanthene in aqueous solution, wherein said halogenated xanthene is a compound selected from the group consisting of 4,5,6,7-Tetrabromoerythrosin, Monobromoerythrosin, Dibromoerythrosin, Tribromoerythrosin, Monochloroerythrosin, Dichloroerythrosin, and Trichloroerythrosin, ~~Monofluoroerythrosin, Difluoroerythrosin, Trifluoroerythrosin, 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein, 2',4,5,6,7,7'-Hexafluorofluorescein, and 4,5,6,7-Tetrafluorofluorescein~~; wherein said halogenated xanthene does not contain a functional derivative at position the functionalities at positions R<sup>1</sup> and R<sup>2</sup> each comprise an element selected from the group consisting of sodium, potassium and hydrogen, and wherein said pharmaceutical composition is for chemotherapeutic treatment of diseases of human and animal tissue.

2 (Previously presented). The pharmaceutical composition of Claim 1 wherein said halogenated xanthene is present in a concentration of greater than about 0.001% to less than about 20%.

3-8 (Canceled).

9 (Previously presented). The pharmaceutical composition of Claim 1 wherein said solution includes an adjuvant selected from the group consisting of builders, stabilizers, emulsifiers, dispersants, preservatives, buffers and electrolytes.

10 (Previously presented). The pharmaceutical composition of Claim 1 wherein said pharmaceutical composition is for the treatment of indications selected from the group consisting of diseases of the skin and related organs, diseases of the mouth and digestive tract and related organs, diseases of the urinary and reproductive tracts and related organs, diseases of the respiratory tract and related organs, diseases of the circulatory system and related organs, diseases of the head and neck, diseases of the endocrine and lymphoreticular systems and related organs, diseases of connective tissues, diseases of tissue surfaces exposed during surgery, and diseases caused by microbial, viral, fungal, and parasitic infection.

11 (Previously presented). The pharmaceutical composition of Claim 1 wherein said medicament is administered using an intracorporeal route of administration selected from the group consisting of intravenous injection, intraperitoneal injection, intramuscular injection, intracranial injection, intratumoral injection, intraepithelial injection, transcutaneous delivery, per oesophageal administration, intraabdominal administration, intraappendicular administration, intraarterial administration, intraarticular administration, intrabronchial administration, intrabuccal administration, intracapsular administration, intracardial administration, intracartilaginous administration, intracavitory administration, intracephalic administration, intracolic administration, intracutaneous administration, intracystic administration, intradermal administration, intraductal

administration, intraduodenal administration, intrafascicular administration, intrafat administration, intrafilar administration, intrafissural administration, intragastric administration, intraglandular administration, intrahepatic administration, intraintestinal administration, intralamellar administration, intralesional administration, intraligamentous administration, intralingual administration, intramammary administration, intramedullary administration, intrameningeal administration, intramyocardial administration, intranasal administration, intraocular administration, intraoperative administration, intraoral administration, intraosseous administration, intraovarian administration, intrapancreatic administration, intraparietal administration, intrapelvic administration, intrapericardial administration, intraperineal administration, intraperitoneal administration, intraplacental administration, intrapleural administration, intrapontine administration, intraprostatic administration, intrapulmonary administration, intrarachidian administration, intrarectal administration, intrarenal administration, intrascleral administration, intrascrotal administration, intrasegmental administration, intrasellar administration, intraspinal administration, intrasplenic administration, intrasternal administration, intrastromal administration, intrasynovial administration, intratarsal administration, intratesticular administration, intrathoracic administration, intratonsillar administration, intratracheal administration, intratubal administration, intratympanic administration, intraureteral administration, intraurethral administration, intrauterine administration, intravaginal administration, intravascular administration, intraventricular administration, intravertebral administration, intravesical administration, and intravitreous administration.

12-18 (Canceled).

19 (Currently amended). A chemotherapeutic pharmaceutical composition for intracorporeal administration consisting of a halogenated xanthene formulated in a delivery vehicle consisting of a tablet, a capsule, or a suppository, wherein said halogenated xanthene is a compound selected from the group consisting of 4,5,6,7-Tetrabromoerythrosin, Monobromoerythrosin, Dibromoerythrosin, Tribromoerythrosin, Monochloroerythrosin, Dichloroerythrosin, and Trichloroerythrosin, ~~Monofluoroerythrosin, Difluoroerythrosin, Trifluoroerythrosin, 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein, 2',4,5,6,7,7'-Hexafluorofluorescein, and 4,5,6,7-Tetrafluorofluorescein~~, and wherein ~~said halogenated xanthene does not contain a functional derivative at position the functionalities at positions R<sup>1</sup> and or R<sup>2</sup> each comprise an element selected from the group consisting of sodium, potassium and hydrogen.~~

20-26 (Canceled).

27 (Previously presented). The pharmaceutical composition of Claim 19 wherein said delivery vehicle includes an adjuvant selected from the group consisting of builders, stabilizers, emulsifiers, dispersants, preservatives, buffers and electrolytes.

36 (New). An injectable chemotherapeutic pharmaceutical composition consisting of a halogenated xanthene in aqueous solution, wherein said halogenated xanthene is a compound selected from the group consisting of 4,5,6,7-Tetrabromoerythrosin, Monobromoerythrosin, Dibromoerythrosin, Tribromoerythrosin, Monochloroerythrosin, Dichloroerythrosin, and Trichloroerythrosin, wherein the functionalities at positions R<sup>1</sup> and R<sup>2</sup> each comprise an element

selected from the group consisting of sodium, potassium and hydrogen, said halogenated xanthene present in a concentration of greater than about 0.001% to less than about 20%, and wherein said pharmaceutical composition is for chemotherapeutic treatment of diseases of human and animal tissue.

37 (New). An injectable chemotherapeutic pharmaceutical composition consisting of a halogenated xanthene in aqueous solution, wherein said halogenated xanthene is a compound selected from the group consisting of 4,5,6,7-Tetrabromoerythrosin, Monobromoerythrosin, Dibromoerythrosin, Tribromoerythrosin, Monochloroerythrosin, Dichloroerythrosin, and Trichloroerythrosin, wherein the functionalities at positions R<sup>1</sup> and R<sup>2</sup> each comprise an element selected from the group consisting of sodium, potassium and hydrogen, said halogenated xanthene present in a concentration of about 10%, and wherein said pharmaceutical composition is for chemotherapeutic treatment of diseases of human and animal tissue.